LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Latigo Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 3, 2026
$14.30+0.30 (+2.14%)
Close on Oct 19, 2026
- Market cap
- $13.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Latigo Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Latigo Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $14.13M | $166.30M |
| Enterprise Value | -$40.87M | $88.19M |
Balance sheet
| Measure | Latigo Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $55.00M | $61.43M |
| Net Cash (Debt) | $55.00M | $15.35M |
| Net Cash Per Share | $55.66 | $0.66 |
| Equity (Book Value) | -$276.08M | $49.09M |
| Book Value Per Share | -$279.37 | $1.37 |
| Tangible Book Value | -$276.08M | $23.52M |
| Working Capital | $7.62M | $76.81M |
Financial position
| Measure | Latigo Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.15 | 3.34 |
| Quick Ratio | 1.07 | 2.44 |
Dividends and yields
| Measure | Latigo Biotherapeutics | Industry median |
|---|---|---|
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Latigo Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 988,236 | 58,127,000 |
Scores
| Measure | Latigo Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -6.01 | -0.22 |
Calculated by StockData from Latigo Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.